Carvykti® (ciltacabtagene autoleucel)
for Multiple Myeloma

Carvykti (ciltacabtagene autoleucel) is a BCMA-directed CAR-T therapy used to treat relapsed or refractory multiple myeloma (RRMM) in adults who have received at least one prior therapy including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. It is a one-time infusion made from the patient’s own T cells, which are genetically modified to recognize and destroy BCMA-expressing myeloma cells.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Multiple Myeloma